NCT03132675 (Keynote-695) is a Phase 2 clinical trial of tavokinogene telseplasmid in Stage III/IV Melanoma, sponsored by OncoSec Medical Incorporated.

Who is sponsoring NCT03132675?

NCT03132675 is sponsored by OncoSec Medical Incorporated.

What drugs are being tested in NCT03132675?

Interventions in NCT03132675: tavokinogene telseplasmid, Pembrolizumab, ImmunoPulse.

What condition does NCT03132675 study?

NCT03132675 studies Stage III/IV Melanoma.

Is NCT03132675 still recruiting?

NCT03132675 is currently status unknown. Last updated 27 March 2023.

Last reviewed 2023-03-27 · How we verify

NCT03132675: Keynote-695

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment

Status unknown Phase 2 Last updated 27 March 2023

What this trial tests

Phase 2 trial testing tavokinogene telseplasmid in Stage III/IV Melanoma in 143 participants. Status unknown.

Timeline

3 October 2017

Primary endpoint
31 March 2023

31 July 2024

Quick facts

Lead sponsor	OncoSec Medical Incorporated
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	143
Start date	3 October 2017
Primary completion	31 March 2023
Estimated completion	31 July 2024
Sites	33 locations across Italy, Canada, Switzerland, Australia, United States

Drugs / interventions tested

tavokinogene telseplasmid — full drug profile →
Pembrolizumab (pembrolizumab) — full drug profile →
ImmunoPulse

Conditions studied

Stage III/IV Melanoma — all drugs for Stage III/IV Melanoma →

Sponsor

OncoSec Medical Incorporated — full company profile →

Who can join

18 and older, any sex, with Stage III/IV Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Keynote 695 is Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab or nivolumab.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, et al · · 2019 · cited 834× · PMID 30413827 · DOI 10.1038/s41416-018-0328-y
Interleukins in cancer: from biology to therapy.
Briukhovetska D, Dörr J, Endres S, Libby P, et al · · 2021 · cited 587× · PMID 34083781 · DOI 10.1038/s41568-021-00363-z
IL-12 Family Cytokines in Cancer and Immunotherapy.
Mirlekar B, Pylayeva-Gupta Y. · · 2021 · cited 212× · PMID 33418929 · DOI 10.3390/cancers13020167
Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders.
Maskalenko NA, Zhigarev D, Campbell KS. · · 2022 · cited 174× · PMID 35314852 · DOI 10.1038/s41573-022-00413-7
Single-cell analyses identify circulating anti-tumor CD8 T cells and markers for their enrichment.
Pauken KE, Shahid O, Lagattuta KA, Mahuron KM, et al · · 2021 · cited 109× · PMID 33651880 · DOI 10.1084/jem.20200920
Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma.
Bhatia S, Longino NV, Miller NJ, Kulikauskas R, et al · · 2020 · cited 64× · PMID 31582519 · DOI 10.1158/1078-0432.ccr-19-0972
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.
Yin N, Li X, Zhang X, Xue S, et al · · 2024 · cited 48× · PMID 38773064 · DOI 10.1038/s41392-024-01826-z
Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy.
Mukhopadhyay A, Wright J, Shirley S, Canton DA, et al · · 2019 · cited 41× · PMID 30323352 · DOI 10.1038/s41434-018-0044-5

Verify or expand the search:

Other OncoSec Medical Incorporated trials

Trials by the same sponsor.

NCT02345330 — Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC) · Phase 2 · terminated
NCT01579318 — Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma · Phase 2 · terminated
NCT01502293 — Trial of pIL-12 Electroporation Malignant Melanoma · Phase 2 · completed
NCT01440816 — IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03132675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OncoSec Medical Incorporated
Last refreshed: 27 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03132675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing